Frank S. Czerwiec

ResearcherPublications, citations & collaboration network

Frank S. Czerwiec is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 92 works, 8,017 citations, an h-index of 37 and an i10-index of 53.

Works

8,017

Citations

h-index

i10-index

IDs:OpenAlex

How has Frank S. Czerwiec's publication output changed over time?

ScholarIQpublication output · 2003–2017

Output grew0% over the shown period — from 2 works in 2003 to 2 in 2017.

20032006201020112012201520162017

What are the most-cited papers on Frank S. Czerwiec?

ScholarIQmost cited works

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared J. Grantham, Eiji Higashihara, Ronald D. Perrone, Holly B. Krasa, John Ouyang, Frank S. Czerwiec

New England Journal of Medicine. 20121,606 CitationsOPEN ACCESS

Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia

Robert W. Schrier, Peter Groß, Mihai Gheorghiade, Tomás Berl, Joseph G. Verbalis, Frank S. Czerwiec, Cesare Orlandi

New England Journal of Medicine. 20061,216 CitationsOPEN ACCESS

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Ronald D. Perrone, Gary G. Koch, John Ouyang, Robert D. McQuade, Jaime D. Blais, Frank S. Czerwiec, Olga Sergeyeva

New England Journal of Medicine. 2017624 CitationsOPEN ACCESS

Vasopressin V 2 -Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure

Mihai Gheorghiade, Imran Khan Niazi, John Ouyang, Frank S. Czerwiec, Jun‐ichi Kambayashi, Manuela Zampino, Cesare Orlandi

Circulation. 2003430 Citations

Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia

Tomás Berl, Friederike Quittnat-Pelletier, Joseph G. Verbalis, Robert W. Schrier, Daniel G. Bichet, John Ouyang, Frank S. Czerwiec

Journal of the American Society of Nephrology. 2010350 Citations